When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PFE - Two-drug HIV regimen on par with three-drug treatment
Pfizer Inc.
48-week results from two Phase 3 clinical trials, ATLAS and FLAIR, evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson (JNJ-0.6%) unit Janssen Therapeutics' Edurant (rilpivirine), injected every four weeks, demonstrated non-inferiority (no worse than) to three-drug Triumeq (abacavir/dolutegravir/lamivudine), taken orally each day, in maintaining viral suppression in adults with HIV-1 infection. The data were presented at the Conference on Retroviruses and Opportunistic Infections in Seattle, WA.
More news on: Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Healthcare stocks news,